Boehringer’s Slashed Cyltezo Salesforce Reflects Struggles For US Humira Biosimilars

Firm Concedes That Adoption Of Adalimumab Rivals ‘Has Not Reached Anticipated Potential’

 
• By David Wallace
  
Chain of paper figures, cut with scissors
Boehringer has cut sales staff for its Humira biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products